Trial Protocol ID USOR 22272_KRT-232-118 | GOG 3089

Trial Description

A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects with TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy (KRT-232-118)

Contact us regarding Clinical Trials at or call us at 877-664-7724


  • Vinni Juneja, M.D.

Disease Types


  • GOG Foundation
  • Kartos Therapeutics NCT ID

  • NCT05797831